attyloid is granting access to its proprietary technology as clinical and pre-clinical drug development tool, particularly as biomarker assay for de-risked pharmaceutical drug development.
Furthermore, outside the applicability as biomarker assay, various iterations and custom-made modifications of attyloid’s core technology sFIDA allow the generation of added value in each, and across all, of these R&D work packages.
In this manner, attyloid enables its collaboration partners to generate higher-quality biologicals with increased reproducibility, saving time and cost for the R&D partner.
attyloid collaborates with pharma, biotech and biosimilar companies in risk-sharing partnership models, as a Preferred Partner
(not as CRO or service provider) over the course of only a defined period or the whole R&D process, from discovery-stage through
pre-clinical R&D and clinical trials to commercial stage.
Get in Touch
Fon +49 (0) 2461 619532
Fon +49 (0) 211 8110377
Fax +49 (0) 2461 619497